Clinical manifestations and longterm followup of a patient with CINCA/NOMID syndrome

Journal of Rheumatology

Volumn 37, Issue 10, 2010, Pages 2196-2197

  Ebrahimi Fakhari, Darius ^a   Wahlster, Lara ^a   Mackensen, Friederike ^a   Blank, Norbert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CANAKINUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A;

ACUTE KIDNEY FAILURE; ADULT; BRAIN ATROPHY; BRAIN VENTRICLE DILATATION; CASE REPORT; CHRONIC KIDNEY FAILURE; CINCA SYNDROME; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FACE; FAILURE TO THRIVE; FEMALE; FEVER; FIBROMYALGIA; FOLLOW UP; FRONTAL BOSSING; GASTROENTERITIS; GENE MUTATION; GENETIC ANALYSIS; GLOMERULONEPHRITIS; HEARING IMPAIRMENT; HUMAN; INJECTION SITE PAIN; INTRAOCULAR PRESSURE; IRON DEFICIENCY ANEMIA; KERATOPATHY; KIDNEY FUNCTION; LASER COAGULATION; LEG; LETTER; LOW DRUG DOSE; LYMPHADENOPATHY; NECROSIS; NOSE MALFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE ATROPHY; OPTIC NEURITIS; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RECURRENT DISEASE; RENAL PROTECTION; SHORT STATURE; SPLENOMEGALY; TRUNK; URTICARIA; UVEITIS; VASCULITIS; VISUAL IMPAIRMENT;

CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FEMALE; HUMANS; YOUNG ADULT;

EID: 77957885883     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.100290     Document Type: Letter

References (10)

1. Prieur AM, Griscelli C. Arthropathy with rash, chronic meningitis, neurological changes and arthritis. J Pediatr 1981;99:79-83.
2. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203.
3. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8.
4. Prieur AM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001;19:103-6.
5. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010;62:258-67.
6. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25.
7. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005;84:1-11.
8. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum 2005;52:1283-6.
9. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 inhibition. N Engl J Med 2006;355:581-92.
10. Kanariou M, Dracou C, Spanou K, Möller J, Rösen-Wolff A, Schuster V, et al. Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome. Klin Padiatr 2009;221:379-81.